Sign in
Author
|
Conference
|
Journal
|
Organization
|
Year
|
DOI
Look for results that meet for the following criteria:
since
equal to
before
between
and
Search in all fields of study
Limit my searches in the following fields of study
Agriculture Science
Arts & Humanities
Biology
Chemistry
Computer Science
Economics & Business
Engineering
Environmental Sciences
Geosciences
Material Science
Mathematics
Medicine
Physics
Social Science
Multidisciplinary
Keywords
(4)
Biological Indicator
Clinical Study
Hepatic Fibrosis
Liver Biopsy
Subscribe
Academic
Publications
Antifibrotic therapies—emerging biomarkers as treatment end points
Antifibrotic therapies—emerging biomarkers as treatment end points,10.1038/nrgastro.2009.197,Nature Reviews Gastroenterology & Hepatology,Jayant A. Ta
Edit
Antifibrotic therapies—emerging biomarkers as treatment end points
(
Citations: 1
)
BibTex
|
RIS
|
RefWorks
Download
Jayant A. Talwalkar
The emergence of novel pharmacologic therapies for
hepatic fibrosis
holds promise for the management of this condition. Furthermore, novel, biological indices—in addition to liver biopsy—may improve our ability to assess the unique pharmacological effects generated by these agents. This article will attempt to highlight the potential for emerging biomarkers to serve as end points in clinical studies that target salient features of hepatic fibrogenesis.
Journal:
Nature Reviews Gastroenterology & Hepatology - NAT REV GASTROENTEROL HEPATOL
, vol. 7, no. 1, pp. 59-61, 2010
DOI:
10.1038/nrgastro.2009.197
Cumulative
Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
(
dx.doi.org
)
(
www.nature.com
)
Citation Context
(1)
... Such an advance will accelerate the ability to conduct long-term trials of antifibrotic drugs by yielding unambiguous evidence of efficacy
...
Scott L. Friedman
.
Evolving challenges in hepatic fibrosis
References
(27)
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery
(
Citations: 544
)
Mary C Corretti
,
Todd J Anderson
,
Emelia J Benjamin
,
David Celermajer
,
Francois Charbonneau
,
Mark A Creager
,
John Deanfield
,
Helmut Drexler
,
Marie Gerhard-Herman
,
David Herrington
,
Patrick Vallance
,
Joseph Vita
http://academic.research.microsoft.com/io.ashx?type=5&id=32905582&selfId1=0&selfId2=0&maxNumber=12&query=
Journal:
Journal of The American College of Cardiology - J AMER COLL CARDIOL
, vol. 39, no. 2, pp. 257-265, 2002
Endothelial Dysfunction and Damage in Congestive Heart Failure: Relation of Flow-Mediated Dilation to Circulating Endothelial Cells, Plasma Indexes of Endothelial Damage, and Brain Natriuretic Peptide
(
Citations: 59
)
A. Y. Chong
Journal:
Circulation
, vol. 110, no. 13, pp. 1794-1798, 2004
Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C
(
Citations: 39
)
A K P Lim
Journal:
Gut
, vol. 54, no. 1, pp. 128-133, 2005
Identification and Clinical Significance of Circulating Endothelial Progenitor Cells in Human Non-Small Cell Lung Cancer
(
Citations: 47
)
B. Dome
Journal:
Cancer Research - CANCER RES
, vol. 66, no. 14, pp. 7341-7347, 2006
Circulating Endothelial Cells in Cardiovascular Disease
(
Citations: 40
)
Christopher J. Boos
,
Gregory Y. H. Lip
,
Andrew D. Blann
Journal:
Journal of The American College of Cardiology - J AMER COLL CARDIOL
, vol. 48, no. 8, pp. 1538-1547, 2006
Sort by:
Citations
(1)
Evolving challenges in hepatic fibrosis
(
Citations: 9
)
Scott L. Friedman
Journal:
Nature Reviews Gastroenterology & Hepatology - NAT REV GASTROENTEROL HEPATOL
, vol. 7, no. 8, pp. 425-436, 2010